4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Vetoquinol SA (VETO) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Lure, France with about 2,422 employees. Its market capitalization is roughly €824 million. In the fiscal year ended 2025-12-31, VETO reported €526M in revenue and €57M in net income.
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | €526M | €539M | €529M | €540M | — |
| Gross Profit | €393M | €387M | €373M | €380M | — |
| Operating Income (EBIT) | €79M | €76M | €78M | €84M | — |
| Net Income | €57M | €59M | €56M | €48M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | (€10M) | (€10M) | (€10M) | (€10M) | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €764M | €744M | €692M | €652M | — |
| Total Liabilities | €172M | €168M | €165M | €167M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VETO viewer.
About TickerBase · Data methodology & sources · Privacy · Terms